Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: Relation to growth hormone levels and insulin-like growth factor I

Experimental and Clinical Endocrinology and Diabetes

Volumn 105, Issue 6, 1997, Pages 331-335

  Wildbrett, J ^a   Hanefeld, M ^a   Fucker K ^a   Pinzer, T ^a   Bergmann, S ^a   Siegert, G ^a   Breidert, M ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Acromegaly; Fibrinolysis; hGH; IGF I; Lipid metabolism; Lp(a)

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN E; GROWTH HORMONE; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR; SOMATOMEDIN C; TISSUE PLASMINOGEN ACTIVATOR;

ACROMEGALY; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; FEMALE; FIBRINOLYSIS; HUMAN; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MALE; PRIORITY JOURNAL;

EID: 0030828619     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1211774     Document Type: Article

References (24)

1. Angelin B, Rudling M: Growth hormone and hepatic lipoprotein metabolism. Curr Opin Lipidol 5: 160-165, 1994
2. Breidert M, Pinzer T, Wildbrett J, Bornstein SR, Hanefeld M: Long-Term Effect of Octreotide in Acromegaly on Insulin Resistance. Horm Metab Res 27: 226-230, 1995
3. Dahlen, GH: Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 108: 110-126, 1994
4. Daughaday WH, Rotwein P: Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev 10: 68-91, 1989
5. Davidson MB: Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 8: 115-131, 1987
6. Edelberg JM, Gonzales-Gronow M, Pizzo SV: Lipoprotein (a) inhibition of plasminogen activation by tissue type plasminogen activator. Thromb Res 57: 155-162, 1990
7. Eden S, Wiklund O, Oscarsson J, Rosen T, Bengtsson BA: Growth Hormone Treatment of Growth Hormone-Deficient Adults results in a marked increase in Lp(a) and HDL Cholesterol Concentrations. Arteriosclerosis and Thrombosis 13: 296-301, 1993
8. Ezzat, S. Living with Acromegaly: Endocrinol Metab Clin North Am 21: 753-760, 1992
9. Jaross W, Assmann G, Bergmann S, Schulte H, Epping PH, Fraid T, Heinrich J, Martin H, Petersen S, Sandkamp M, Schottmann B, Siegert B, Thulin H, Waheburg U: Comparison of risk factors for coronary heart disease in Dresden and Munster - Results of DRECAN (Dresden cardiovascular risk and nutrition) study and the PROCAM (Prospective cardiovascular Munster study) Eur J of Epidemiol 10: 307-315, 1994
10. Juhan-Vague I, Collen D: On the Role of Coagulation and Fibrinolysis in Atherosclerosis. AEP 2: 427-438, 1992
11. Lam KSL: Serum apolipoprotein(a) correlates with growth hormone levels in chinese patients with acromegaly. Atherosclerosis 104: 183-188, 1993
12. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR: North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet II 533-537, 1986
13. Nachman RL: The 1994 Runme Shaw Memorial Lecture: Thrombosis and Atherogenesis - molecular connections. Ann Acad Med Singapore 24: 281-289, 1995
14. Olivecrona H, Ericsson S, Berghind L, Angelin B: Increased concentrations of serum lipoprotein (a) in response to growth hormone treatment. BMI 306: 1726-1727, 1993
15. Oscarsson J, Wiklund O, Jakobsson KE, Petruson B, Bengtsson BA: Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy. Clin-Endocrinol-Oxf. 41: 603-608, 1994
16. Padayatty SJ, Orme S, Zenobi PD, Stickland MH, Belchets PE, Grant PJ: The effects of insulin-like growth factor-I on plasminogen activator inhibitor-I synthesis and secretion: results from in vitro and in vivo studies. Thromb Haemost 70: 1009-1013, 1993
17. Savage DD, Henry WL, Eastman RC, Borer JS, Gorden P: Echocardiographic assessment of cardiac anatomy and function in acromegalic patients. Am J Med 67: 823-829, 1979
18. Sjoberg A, Oscarsson J, Eden S, Olofsson SO: Continous but not intermittent administration of growth hormone to hypophysectomized rats increased apolipoprotein E secretion from cultured hepatocytes. Endocrinology 134: 790-798, 1994
19. Smallridge RC, Raifer S, Davis J, Schaaf M: Acromegaly and the heart. Am J Med 66: 22, 1979
20. Souadjian JV, Schirger A: Hypertension in acromegaly. Am J Med Sci 254: 629, 1967
21. Stief TW, Lenz P, Becker U, Heimburger N: Determination of plasminogen activator inhibitor (PAI) capacity of human plasma in presence of oxidants: a novel principle. Thromb Res 50: 559-573, 1988
22. Uterman G: The mysteries of Lp(a). Science 1989; 246: 904-910
23. Wright AD, Hill DM, Lowy C, Fraser TR: Mortality in acromegaly. Q J Med 39: 1-16, 1970
24. Woita J, Turcu L, Wagner OF, Korninger C, Binder BR: Evaluation of fibrinolytic capacity by a combined assay system for tissue-type-plasminogen-activator antigen and function using monoclonal anti-tissue-type-plasminogen-activator antibodies. J Lab Clin Med 105: 665-671, 1987